Sera Prognostics Signs Agreement with MultiPlan

Sera Prognostics Inc., “The Pregnancy Company,” focused on improving maternal and neonatal health by providing pregnancy biomarker information to doctors and patients, has announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks.
 
The agreement will help expand access to the PreTRM Test, the company’s proprietary proteomic blood test for measuring a woman’s risk of spontaneous preterm birth, to allow more timely intervention to the members accessing MultiPlan’s services through its more than 700 healthcare payers and the 1.2 million healthcare providers participating in MultiPlan’s provider networks.
 
The PreTRM Test is a broadly clinically validated, commercially available blood-based biomarker test that provides an early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. Ordered by medical professionals, the test empowers physicians to better identify, during the 19th or 20th week of pregnancy, women who are at increased risk for premature delivery. This early knowledge enables these women and their doctors to develop personalized intervention plans designed to improve the outcomes of newborns and mothers.
 
“Our agreement with MultiPlan emphasizes the acknowledgment by the healthcare ecosystem of the important role PreTRM plays in delivering pivotal information to physicians to help improve the health of pregnant women and newborns, and thereby lower healthcare costs,” said Gregory C. Critchfield, MD, MS, chairman and chief executive officer of Sera Prognostics. “This additional significant milestone is another indicator of the growing interest in adopting the PreTRM test and treat strategy as we build commercialization and reimbursement mechanisms with other payers and broaden adoption of the PreTRM Test.”